Insulin analogue therapy in pregnancies complicated by diabetes mellitus

Bibliography

• BLOOMGARDEN ZT: American Diabetes Association 60th Scientific Sessions, 2000. Diabetes Care (2000) 11: 1699-1703.
   Google Scholar
• AMERICAN DIABETES ASSOCIATION STATEMENT ON GESTATIONAL DIABETES MELLITUS: Diabetes Care (2004) 27\(Suppl. 0:88–90.
   Google Scholar
• ••Diagnostic criteria for GDM.
   Google Scholar
• GARG SK, FRIAS JP, ANIL S et al: Insulin lispro therapy in pregnancies complicated by Type 1 diabetes: glycemic control and maternal and fetal outcomes. Endocrine Pract. (2003) 9:187–193.
   PubMedGoogle Scholar
• BRAUNSTEIN GD: Endocrine changes in pregnancy. In: Williams textbook of Endocrinology(10th edition). Larsen PR, Kronenberg HM, Melmed S, Polonsky KS (Eds), W.B. Saunders, Philadelphia (2002) 795–810.
   Google Scholar
• CYPRYC K, SOB CZAK M, MARCZEWSKA M et al.: Pregnancy complications and perinatal outcomes in diabetic women treated with humalog (insulin lispro) or regular insulin during pregnancy. Med. Sci. Mond (2004) 10(2) :P129–P32.
   Google Scholar
• CASSON IF, CLARKE CA, HOWARD CV et al.: Outcomes of pregnancy in insulin dependent diabetic women: results of a five year population cohort study. BE Med. J. (1997) 315(7130):275–278.
   PubMedGoogle Scholar
• ABERG A, WESTBOM L, KALLEN B: Congenital malformations among infants whose mothers had gestational diabetes or preexisting diabetes. Early Hum. Dev. (2001) 61(2):85–89.
   PubMed Web of Science ®Google Scholar
• CUNDY T, GAMBLE G, TOWNEND K et al.: Perinatal mortality in Type 2 diabetes mellitus. Diabet. Med. (2000) 17(1):33–39.
   PubMed Web of Science ®Google Scholar
• ORSKOU J, KESMODEL U, HENRIKSEN TB et al.: An increasing proportion of infants weight more than 4000 grams at birth. Acta. Obstet. Scand. (2001) 80(10):931–936.
   PubMedGoogle Scholar
• RAYCHAUDHURI K, MARESH MJ: Glycemic control throughout pregnancy and fetal growth in insulin dependent diabetes. Obstet. Cynecol (2000) 95(2):190–194.
   Google Scholar
• COMBS CA, GUNDERSON E, KITZMILLER JL: Relationship of fetal macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care (1992) 15(10):1251–1257.
   PubMed Web of Science ®Google Scholar
• ••Relationship between postprandialglycaemia and macrosomia.
   Google Scholar
• MANDERSON JG, PATTERSON CC, HADDEN DR et al.: Preprandial versus postprandial blood glucose monitoring in Type 1 diabetic pregnancy: a randomized controlled clinical trial. Am. J. Obstet. Cynecol (2003) 189(2):507–5l2.
   Google Scholar
• ••Importance of postprandial hyperglycaemia in diabetic preganacies.
   Google Scholar
• PARFITT VJ, CLARK JD, TURNER GM et al.: Maternal postprandial blood glucose levels influence infant birth weight in diabetic pregnancy. Diabetes Res. (1992) 19(3):133–135.
   PubMedGoogle Scholar
• SIMMONS VD: The utility and efficacy of the new insulins in the management of diabetes and pregnancy. Curr. Diab. Rep. (2002) 2(4):331–336.
   PubMedGoogle Scholar
• ••Goal of therapy for diabetes in pregnancy.
   Google Scholar
• BOLLI GB, MARCHI RD, PARK GD et al.: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia (1999) 42:1151–1167.
   PubMed Web of Science ®Google Scholar
• Insulin pharmacology. In: Textbook of diabetes 2 Ord edition). Pickup J, Williams G (Eds), Blackwell Publishing, Oxford (2003) 8–11.
   Google Scholar
• SIEBENHOFFER A, PLANK J, BERGHOLD A et al.: Short acting insulin analogs versus regular human insulin in patients with diabetes mellitus. The Cochrane Database of Systematic Reviews (2004) Issue 4. Art. Number:CD003287.pub 3. DOI: 10.1002/14651858.CD003287.pub 3.
   Google Scholar
• SIEBENHOFFER A, PLANK J, BERGHOLD A et al.: Meta-analysis of short acting insulin analogs in adults patients with Type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. Diabetologia (2004) 47: 1895-1905.
   Google Scholar
• KURTZHALS P: Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir. Int. J. Obes. Relat. Metab. Disord. (2004) 28\(Suppl. 2):S23–28.
   Google Scholar
• HERMANSEN K, MADSBAD S, PERRILD H et al.: Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in Type 1 diabetic subjects on basal-bolus therapy. Diabetes Care (2001) 24(2):296–301.
   PubMed Web of Science ®Google Scholar
• NORMAN RJ, WANG JX, HAGUE W: Should we continue or stop insulin sensitizing drugs during pregnancy? Curr. Opin. Obstet. Cynecol. (2004) 16(3):245–250.
   PubMedGoogle Scholar
• SIMMONS D, WALTERS BN, ROWAN JA et al.: Metformin therapy and diabetes in pregnancy. Med. J. Aust. (2004) 181(3):174–175.
   PubMedGoogle Scholar
• GLUECK CJ, GOLDENBERG N, WANG P et al: Metformin during pregnancy reduces insulin, insulin resistance, insulin secretion, weight, testosterone and development of gestational diabetes: prospective longitudinal assessment of women with polycystic ovary syndrome from preconception throughout pregnancy. Hum. Reprod. (2004) 19(3):510–521.
   PubMed Web of Science ®Google Scholar
• MCCARTHY EA, WALKER SP, MCLACHLAN K et al: Metformin in obstetric and gynecologic practice: a review. Obstet. Cynecol. Sun'. (2004) 59(2):118–127.
   PubMedGoogle Scholar
• GLUECK CJ, GOLDENBERG N, STRETCHER P et al: Metformin and gestational diabetes. Curr. Blab. Rep. (2003) 3(4):303–312.
   PubMedGoogle Scholar
• PERSSON B, SWAHN ML, HJERTBERG R et al: Insulin lispro therapy in pregnancies complicated by Type 1 diabetes mellitus. Diabetes Res. Clin. Pract. (2002) 58(2):115–121.
   PubMed Web of Science ®Google Scholar
• GAMSON K, CHIA S, JOVANOVIC L: The safety and efficacy of insulin analogs in pregnancy. J. Matem. Fetal Neonatal Med. (2004) 15:26–34.
   PubMedGoogle Scholar
• ••Complete review on analogues andpregnancy.
   Google Scholar
• VANHAVERBEKE G, MERTENS A, MATHIEU C: Diabetic management in high risk patients. Acta Clia Belg. (2004) 59(0173–181.
   PubMed Web of Science ®Google Scholar
• SIMMON D, THOMPSON CE CONROY C et al: Use of insulin pumps in pregnancies complicated by Type 2 diabetes and gestational diabetes in a multiethnic community. Diabetes Care. (2001) 24(12):2078–2082.
   PubMedGoogle Scholar
• RENARD E, RAINGEARD I, BOULOT P et al.: Insulin therapy in Type 1 diabetes for and during pregnancy: by which means and for which objectives. Diabetes Metab. (2001) 27(4 Pt 2): S61–S66.
   Google Scholar
• MECACCI F, CARIGNANI L, CIONI R et al.: Maternal metabolic control and perinatal outcome in women with gestational diabetes treated with regular or lispro insulin: comparison with non- diabetic pregnant women. Eur. j Obstet. Cynecol. Reprod. Biol. (2003) 111(1):19–24.
   PubMed Web of Science ®Google Scholar
• MASSON EA, PATMORE JE, BRASH PD et al: Pregnancy outcome in Type 1 diabetes mellitus treated with insulin lispro (Humalog). Diabet. Med. (2003) 20(1):46–50.
   PubMedGoogle Scholar
• PETTITT DJ, OSPINA P, KOLACZYNSKI JW et al: Comparison of an insulin analog, insulin aspart, and regular human insulin with no insulin in gestational diabetes mellitus. Diabetes Care (2003) 26(1):183–186.
   PubMed Web of Science ®Google Scholar
• ••Compares both insulin lispro and insulinaspart with regular insulin.
   Google Scholar
• PERSSON B, SWAHN ML, HJERTBERG R et al: Insulin lispro therapy in pregnancies complicated by Type 1 diabetes mellitus. Diabetes Res. Clin. Pict. (2002) 58(2):115–121.
   PubMed Web of Science ®Google Scholar
• JOVANOVIC L, ILIC S, PETTITT DJ et al: Metabolic and immunologic effects of insulin lispro in gestational diabetes. Diabetes Care (1999) 22:1422–1427.
   PubMed Web of Science ®Google Scholar
• ••Complete description about metaboliceffects of insulin lispro in GDM.
   Google Scholar
• KITZMILLER JL, MAIN E, WARD B et al.: Insulin lispro and the development of proliferative diabetic retinopathy during pregnancy. Diabetes Care (1999) 22:874–876.
   PubMed Web of Science ®Google Scholar
• ••Full description of insulin lispro andretinopathy in pregnancy.
   Google Scholar
• JOVANOVIC L: Retinopathy risk: what is responsible? Hormones, hyperglycemia, or humalog? Diabetes Care (1999) 22:846–848.
   Google Scholar
• LOUKOVARRA S, IMMONEN I, TERAMO KA et al.: Progression of retinopathy during pregnancy in Type 2 diabetic women treated with insulin lispro. Diabetes Care (2003) 26:1193–1198.
   PubMedGoogle Scholar
• ••Full description of insulin lispro andretinopathy in pregnancy.
   Google Scholar
• MENON RK, COHEN RM, SPERLING MA et al.: Transplacental passage of insulin in pregnant women with insulin dependent diabetes mellitus. N Engl. J. Med. (1992) 326(4):280.
   Google Scholar
• BOSKOVIC R, FEIG DS, DEREWLANY L et al.: Transfer of insulin lispro across the human placenta: in vitro perfusion studies. Diabetes Care (2003) 26(5):1390–1394.
   PubMedGoogle Scholar
• KURTZHALS P, SCHAFFER L, KRISTENSEN C et al.: Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes (2000) 49:999–1005.
   PubMed Web of Science ®Google Scholar
• DIAMOND T, KORMAS N: Possible adverse fetal effect of insulin lispro. N Engl. J. Med. (1997) 337:1009; author reply 1010.
   Google Scholar
• ANDERSON H, BASTYR E, WISHNER K et al.: Letter to the Editor in response to Posible adverse fetal effect of insulin lispro'. N Engl. J. Med. (1997) 337:1009–1010.
   PubMedGoogle Scholar
• DE VECIANA M, MAJOR CA, MORGAN MA et al: Posprandial versus preprandial blood glucose monitoring in woman with gestational diabetes mellitus requiring insulin therapy. N Engl. I Med. (1995) 333:1237–1241.
   PubMed Web of Science ®Google Scholar
• ••Importance of postprandial glucosemonitoring in GDM.
   Google Scholar